New drug developments in metastatic gastric cancer

被引：19

作者：

Tan, Aaron C. ^{[2
,3
]}

Chan, David L. ^{[2
,4
]}

Faisal, Wasek ^{[5
]}

Pavlakis, Nick ^{[1
]}

机构：

[1] Royal North Shore Hosp, Northern Sydney Canc Ctr, Reserve Rd, St Leonards, NSW 2065, Australia

[2] Royal North Shore Hosp, Northern Sydney Canc Ctr, Sydney, NSW, Australia

[3] Natl Canc Ctr, Singapore, Singapore

[4] Univ Sydney, Northern Clin Sch, Sydney, NSW, Australia

[5] Ballarat Reg Integrated Canc Ctr, Ballarat, Vic, Australia

来源：

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2018年 / 11卷

关键词：

gastric cancer; immunotherapy; targeted therapy; GASTROESOPHAGEAL JUNCTION CANCER; RANDOMIZED PHASE-II; DOUBLE-BLIND; 1ST-LINE THERAPY; OPEN-LABEL; PLUS PACLITAXEL; ADENOCARCINOMA; CAPECITABINE; CHEMOTHERAPY; MET;

D O I：

10.1177/1756284818808072

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Metastatic gastric cancer is associated with a poor prognosis and novel treatment options are desperately needed. The development of targeted therapies heralded a new era for the management of metastatic gastric cancer, however results from clinical trials of numerous targeted agents have been mixed. The advent of immune checkpoint inhibitors has yielded similar promise and results from early trials are encouraging. This review provides an overview of the systemic treatment options evaluated in metastatic gastric cancer, with a focus on recent evidence from clinical trials for targeted therapies and immune checkpoint inhibitors. The failure to identify appropriate predictive biomarkers has hampered the success of many targeted therapies in gastric cancer, and a deeper understanding of specific molecular subtypes and genomic alterations may allow for more precision in the application of novel therapies. Identifying appropriate biomarkers for patient selection is essential for future clinical trials, for the most effective use of novel agents and in combination approaches to account for growing complexity of treatment options.

引用

页数：13

共 89 条

[1] Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial [J].

Ajani, Jaffer A. ;

Rodriguez, Wuilbert ;

Bodoky, Gyorgy ;

Moiseyenko, Vladimir ;

Lichinitser, Mikhail ;

Gorbunova, Vera ;

Vynnychenko, Ihor ;

Garin, August ;

Lang, Istvan ;

Falcon, Silvia .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) :1547-1553

[2] Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin:: A study of the arbeitsgemeinschaft internistische onkologie [J].

Al-Batran, Salah-Eddin ;

Hartmann, Joerg Thomas ;

Probst, Stephan ;

Schmalenberg, Harald ;

Hollerbach, Stephan ;

Hofheinz, Ralf ;

Rethwisch, Volker ;

Seipelt, Gernot ;

Homann, Nils ;

Wilhelm, Gerhard ;

Schuch, Gunter ;

Stoehlmacher, Jan ;

Derigs, Hans Guenter ;

Hegewisch-Becker, Susanna ;

Grossmann, Johannes ;

Pauligk, Claudia ;

Atmaca, Akin ;

Bokemeyer, Carsten ;

Knuth, Alexander ;

Jaeger, Elke .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) :1435-1442

[3]

[Anonymous], 2015, J CLIN ONCOL S

[4]

[Anonymous], ANN ONCOL S5

[5]

[Anonymous], ANN ONCOL

[6]

[Anonymous], 2018, J CLIN ONCOL S

[7] MET Signaling Pathway: A Rational Target for Cancer Therapy [J].

Appleman, Leonard J. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (36) :4837-4838

[8] Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 [J].

Bang, Y. -J. ;

Ruiz, E. Yanez ;

Van Cutsem, E. ;

Lee, K. -W. ;

Wyrwicz, L. ;

Schenker, M. ;

Alsina, M. ;

Ryu, M. -H. ;

Chung, H. -C. ;

Evesque, L. ;

Al-Batran, S. -E. ;

Park, S. H. ;

Lichinitser, M. ;

Boku, N. ;

Moehler, M. H. ;

Hong, J. ;

Xiong, H. ;

Hallwachs, R. ;

Conti, I. ;

Taieb, J. .

ANNALS OF ONCOLOGY, 2018, 29 (10) :2052-2060

[9]

Bang YJ, 2010, LANCET, V376, P1302

[10] Comprehensive molecular characterization of gastric adenocarcinoma [J].

Bass, Adam J. ;

Thorsson, Vesteinn ;

Shmulevich, Ilya ;

Reynolds, Sheila M. ;

Miller, Michael ;

Bernard, Brady ;

Hinoue, Toshinori ;

Laird, Peter W. ;

Curtis, Christina ;

Shen, Hui ;

Weisenberger, Daniel J. ;

Schultz, Nikolaus ;

Shen, Ronglai ;

Weinhold, Nils ;

Keiser, David P. ;

Bowlby, Reanne ;

Sipahimalani, Payal ;

Cherniack, Andrew D. ;

Getz, Gad ;

Liu, Yingchun ;

Noble, Michael S. ;

Pedamallu, Chandra ;

Sougnez, Carrie ;

Taylor-Weiner, Amaro ;

Akbani, Rehan ;

Lee, Ju-Seog ;

Liu, Wenbin ;

Mills, Gordon B. ;

Yang, Da ;

Zhang, Wei ;

Pantazi, Angeliki ;

Parfenov, Michael ;

Gulley, Margaret ;

Piazuelo, M. Blanca ;

Schneider, Barbara G. ;

Kim, Jihun ;

Boussioutas, Alex ;

Sheth, Margi ;

Demchok, John A. ;

Rabkin, Charles S. ;

Willis, Joseph E. ;

Ng, Sam ;

Garman, Katherine ;

Beer, David G. ;

Pennathur, Arjun ;

Raphael, Benjamin J. ;

Wu, Hsin-Ta ;

Odze, Robert ;

Kim, Hark K. ;

Bowen, Jay .

NATURE, 2014, 513 (7517) :202-209

← 1 2 3 4 5 6 7 8 9 →